Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers

Cell Cycle

Volumn 11, Issue 13, 2012, Pages 2518-2525

  Rick, Ferenc G ^a,b   Buchholz, Stefan ^a,b,c   Schally, Andrew V ^a,b   Szalontay, Luca ^a   Krishan, Awtar ^b   Datz, Christian ^d,e   Stadlmayr, Andreas ^d,e   Aigner, Elmar ^d,e   Perez, Roberto ^a,b   Seitz, Stephan ^a,b,c   Block, Norman L ^a,b   Hohla, Florian ^a,b,e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

5 FU; BN GRP antagonist; Colon cancer; Cytotoxic agents; Irinotecan; RC 3940 II; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; GASTRIN RELEASING PEPTIDE RECEPTOR; IRINOTECAN; RC 3940; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; COLON CANCER; CONTROLLED STUDY; DNA CONTENT; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; TUMOR XENOGRAFT;

MUS MUSCULUS;

EID: 84863800757     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20900     Document Type: Article

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008; 58:71-96; PMID:18287387; http://dx.doi.org/ 10.3322/CA.2007.0010.
2. Fuchs CS, Marshall J, Mitchell E, Wierzbicki R, Ganju V, Jeffery M, et al. Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 2007; 25:4779-86; PMID:17947725; http://dx.doi.org/10.1200/JCO.2007.11.3357.
3. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-37; PMID:14657227; http://dx.doi.org/10.1200/JCO.2004.05.113.
4. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42; PMID:15175435; http://dx.doi.org/10.1056/NEJMoa032691.
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408-17; PMID:19339720; http://dx.doi.org/10.1056/NEJMoa0805019.
6. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28:4697-705; PMID:20921465; http://dx.doi.org/10.1200/JCO.2009.27.4860.
7. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, et al. Hypothalamic hormones and cancer. Front Neuroendocrinol 2001; 22:248-91; PMID:11587553; http://dx.doi.org/10.1006/frne.2001.0217.
8. Patel O, Shulkes A, Baldwin GS. Gastrin-releasing peptide and cancer. Biochim Biophys Acta 2006; 1766:23-41; PMID:16490321.
9. Corral RS, Iñiguez MA, Duque J, López-Pérez R, Fresno M. Bombesin induces cyclooxygenase-2 expression through the activation of the nuclear factor of activated T cells and enhances cell migration in Caco-2 colon carcinoma cells. Oncogene 2007; 26:958-69; PMID:16909108; http://dx.doi.org/10. 1038/sj.onc.1209856.
10. Thomas RP, Hellmich MR, Townsend CM Jr, Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr Rev 2003; 24:571-99; PMID:14570743; http://dx.doi.org/10.1210/er.2002- 0028.
11. 2 or its derivatives. Proc Natl Acad Sci USA 1994; 91:12664-8; PMID:7809097; http://dx.doi.org/10.1073/ pnas.91.26.12664.
12. Radulovic S, Miller G, Schally AV. Inhibition of growth of HT-29 human colon cancer xenografts in nude mice by treatment with bombesin/gastrin- releasing peptide antagonist (RC-3095). Cancer Res 1991; 51:6006-9; PMID:1682040.
13. Radulovic S, Schally AV, Reile H, Halmos G, Szepeshazi K, Groot K, et al. Inhibitory effects of antagonists of bombesin/gastrin-releasing peptide (GRP) and somatostatin analog (RC-160) on growth of HT-29 human colon cancers in nude mice. Acta Oncol 1994; 33:693-701; PMID:7946450; http://dx.doi.org/10.3109/ 02841869409121784.
14. 2. Int J Oncol 1995; 7:749-54; PMID:21552898.
15. 2 show high binding-affinity to bombesin/grp receptors on cfpac-1 human pancreatic-cancer cells. Int J Oncol 1995; 6:1165-72; PMID:21556653.
16. Kanashiro CA, Schally AV, Cai RZ, Halmos G. Antagonists of bombesin/gastrin-releasing peptide decrease the expression of angiogenic and anti-apoptotic factors in human glioblastoma. Anticancer Drugs 2005; 16:159-65; PMID:15655413; http://dx.doi.org/10.1097/00001813-200502000-00007.
17. Bajo AM, Schally AV, Groot K, Szepeshazi K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br J Cancer 2004; 90:245-52; PMID:14710236; http://dx.doi.org/10.1038/sj.bjc.6601404.
18. Hohla F, Schally AV, Kanashiro CA, Buchholz S, Baker B, Kannadka C, et al. Growth inhibition of non-small-cell lung carcinoma by BN/GRP antagonist is linked with suppression of K-Ras, COX-2 and pAkt. Proc Natl Acad Sci USA 2007; 104:18671-6; PMID:18003891; http://dx.doi.org/10.1073/pnas.0709455104.
19. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, et al. Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II. Cancer 1998; 82:909-17; PMID:9486581; http://dx.doi.org/10.1002/(SICI)1097-0142(19980301)82:5〈909:: AIDCNCR16〉3.0.CO;2-4.
20. Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. Cancer Lett 2005; 226:123-31; PMID:16039952; http://dx.doi.org/10.1016/j.canlet.2005. 01.008.
21. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, et al. Inhibition of human androgenin-dependent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer 2005; 41:2735-44; PMID:16291086; http://dx.doi.org/10.1016/j.ejca.2005.08.022.
22. Schally AV, Szepeshazi K, Nagy A, Comaru-Schally AM, Halmos G. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs. Cell Mol Life Sci 2004; 61:1042-68; PMID:15112052; http://dx.doi.org/10.1007/s00018-004-3434-3.
23. Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling and functions in normal and disease states. Pharmacol Rev 2008; 60:1-42; PMID:18055507; http://dx.doi.org/10.1124/pr.107.07108.
24. Gorbulev V, Akhundova A, Büchner H, Fahrenholz F. Molecular cloning of a new bombesin receptor subtype expressed in uterus during pregnancy. Eur J Biochem 1992; 208:405-10; PMID:1325907; http://dx.doi.org/10.1111/j.1432-033. 1992.tb17201.x.
25. Ferris HA, Carroll RE, Lorimer DL, Benya RV. Location and characterization of the human GRP receptor expressed by gastrointestinal epithelial cells. Peptides 1997; 18:663-72; PMID:9213359; http://dx.doi.org/10. 1016/S0196-9781(97)00127-7.
26. Carroll RE, Matkowskyj KA, Chakrabarti S, McDonald TJ, Benya RV. Aberrant expression of gastrin-releasing peptide and its receptor by well-differentiated colon cancers in humans. Am J Physiol 1999; 276:655-65; PMID:10070042.
27. Chave HS, Gough AC, Palmer K, Preston SR, Primrose JN. Bombesin family receptor and ligand gene expression in human colorectal cancer and normal mucosa. Br J Cancer 2000; 82:124-30; PMID:10638978.
28. Patel O, Dumesny C, Giraud AS, Baldwin GS, Shulkes A. Stimulation of proliferation and migration of a colorectal cancer cell line by amidated and glycine-extended gastrin-releasing peptide via the same receptor. Biochem Pharmacol 2004; 68:2129-42; PMID:15498503; http://dx.doi.org/10.1016/j.bcp.2004. 08.009.
29. Radulovic SS, Milovanovic SR, Cai RZ, Schally AV. The binding of bombesin and somatostatin and their analogs to human colon cancers. Proc Soc Exp Biol Med 1992; 200:394-401; PMID:1352046.
30. Preston SR, Woodhouse LF, Jones-Blackett S, Miller GV, Primrose JN. High-affinity binding sites for gastrin-releasing peptide on human colorectal cancer tissue but not uninvolved mucosa. Br J Cancer 1995; 71:1087-9; PMID:7734305; http://dx.doi.org/10.1038/bjc.1995.210.
31. Saurin JC, Rouault JP, Abello J, Berger F, Remy L, Chayvialle JA. High gastrin-releasing peptide receptor mRNA level is related to tumour dedifferentiation and lymphatic vessel invasion in human colon cancer. Eur J Cancer 1999; 35:125-32; PMID:10211100; http://dx.doi.org/10.1016/S0959-8049(98) 00276-7.
32. Rozengurt EV. Gastrointestinal peptide signaling through tyrosine phosphorylation of focal adhesion proteins. Am J Physiol 1998; 275:177-82; PMID:9688642.
33. Rozengurt E, Murray M, Zachary I, Collins M. Protein kinase C activation enhances cAMP accumulation in Swiss 3T3 cells: inhibition by pertussis toxin. Proc Natl Acad Sci USA 1987; 84:2282-6; PMID:3031676; http://dx.doi.org/10.1073/ pnas.84.8.2282.
34. Liu X, Carlisle DL, Swick MC, Gaither-Davis A, Grandis JR, Siegfried JM. Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib. Exp Cell Res 2007; 313:1361-72; PMID:17349623; http://dx.doi.org/10.1016/j.yexcr.2007.01.016.
35. Rozengurt E. Signal transduction pathways in the mitogenic response to G protein-coupled neuropeptide receptor agonists. J Cell Physiol 1998; 177:507-17; PMID:10092204; http://dx.doi.org/10.1002/(SICI)1097-4652(199812)177:4〈507: :AIDJCP2〉3.0.CO;2-K.
36. Lui VW, Thomas SM, Zhang Q, Wentzel AL, Siegfried JM, Li JY, et al. Mitogenic effects of gastrin-releasing peptide in head and neck squamous cancer cells are mediated by activation of the epidermal growth factor receptor. Oncogene 2003; 22:6183-93; PMID:13679857; http://dx.doi.org/10.1038/sj.onc. 1206720.
37. Thomas SM, Grandis JR, Wentzel AL, Gooding WE, Lui VW, Siegfried JM. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia 2005; 7:426-31; PMID:15967120; http://dx.doi.org/10.1593/neo.04454.
38. Casanueva FF, Perez FR, Casabiell X, Camiña JP, Cai RZ, Schally AV. Correlation between the effects of bombesin antagonists on cell proliferation and intracellular calcium concentration in Swiss 3T3 and HT-29 cell lines. Proc Natl Acad Sci USA 1996; 93:1406-11; PMID:8643644; http://dx.doi.org/10.1073/ pnas.93.4.1406.
39. Seretis E, Gavrill A, Agnantis N, Golematis V, Voloudakis-Baltatzis IE. Comparative study of serotonin and bombesin in adenocarcinomas and neuroendocrine tumors of the colon. Ultrastruct Pathol 2001; 25:445-54; PMID:11783909; http://dx.doi.org/10.1080/019131201753343485.
40. Szepeshazi K, Schally AV, Groot K, Halmos G. Effect of bombesin, gastrin-releasing peptide (GRP) (14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters. Int J Cancer 1993; 54:282-9; PMID:8387464; http://dx.doi.org/10.1002/ijc.2910540220.
41. Hohla F, Buchholz S, Schally AV, Seitz S, Rick FG, Szalontay L, et al. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle 2009; 8:3149-56; PMID:19755849; http://dx.doi.org/10.4161/cc.8.19.9698.
42. Rick FG, Schally AV, Block NL, Nadji M, Szepeshazi K, Zarandi M, et al. Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 2011; 108:3755-60; PMID:21321192; http://dx.doi.org/10.1073/pnas.1018086108.
43. Rick FG, Schally AV, Szalontay L, Block NL, Szepeshazi K, Nadji M, et al. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA 2012; 109:1655-60; PMID:22307626; http://dx.doi.org/10.1073/pnas.1120588109.
44. Rick FG, Schally AV, Block NL, Halmos G, Perez R, Fernandez JB, et al. LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 2011; 71:736-47; PMID:20945403; http://dx.doi.org/10.1002/ pros.21289.